APTITUDE HEALTH®

CASES

Insights Into Cisplatin-Induced Ototoxicity in Localized, Nonmetastatic Solid Tumors

July – September 2024

Contents

CASES

How to Navigate This Report

Click to move to topic of interest or ARS supporting data



Click to return to previous slide

Report Objectives

MEETING OBJECTIVES
Gain advisors' perspectives on existing and emerging treatments for managing cisplatin-induced toxicities in localized, nonmetastatic solid tumors, including the current landscape, challenges, and future directions

Report Snapshot: Session Overview

A series of 5 moderated virtual roundtable discussions were held with community oncologists from July to September 2024

Disease state and data presentations and discussions were led and moderated by **Noah Federman, MD,** from UCLA David Geffen School of Medicine, and **Ralph V. Boccia, MD, FACP,** from Georgetown University in conjunction with content developed by the Aptitude Health clinical team

Insights were obtained on the cisplatin-induced ototoxicity landscape in the community setting, including occurrence, monitoring, and managing toxicities in patients receiving cisplatin for localized, nonmetastatic solid tumors

Data collection was accomplished through audience response system (ARS) questions and in-depth moderated discussion

Report Snapshot: Attendee Overview

Chicago/Ohio Valley Region
September 23, 2024
6 oncologists

Northeast Region
September 12, 2024
5 oncologists



Pacific Region
September 24, 2024
6 oncologists

Southeast Region
September 24, 2024
6 oncologists

Cancer Center of Kansas
July 25, 2024
Wichita, KS
7 oncologists

	INSTITUTION	CITY	STATE
Southeast Region	Georgia Cancer Specialists	Atlanta	GA
	Northwest Georgia Oncology Centers/ WellStar	Atlanta	
	Northwest Georgia Oncology Centers	Cartersville	
	Atrium Health	Huntersville	NC
	Tennessee Oncology	Shelbyville	TN
	Carolina Blood and Cancer Care Associates	Lancaster	SC
Northeast Region	New York Cancer & Blood Specialists	Port Jefferson	NY
	Hematology-Oncology Associates of CNY	Syracuse	
	Dana-Farber Cancer Institute	Boston	MA
	Abramson Cancer Center Cherry Hill	Cherry Hill	NJ
	Medical Oncology Hematology Consultants	Newark	DE
Pacific Region	Enloe Medical Center	Chico	CA
	Compassionate Cancer Care	Fountain Valley	
	Riverside Medical Center	Riverside	
	Comprehensive Cancer Centers of Nevada	Las Vegas	NV
	Arizona Oncology	Tucson	AZ
	MultiCare Regional Cancer Center	Tacoma	WA
Chicago/Ohio Valley Region	Hematology Oncology of Indiana	Indianapolis	IN
	Northwest Cancer Centers	Valparaiso	
	Illinois Cancer Specialists	Arlington Heights	IL
	York Cancer Center	York	PA
	Hope Center for Cancer Care	Mars	
	UH Seidman Cancer Center	Parma	OH

APTITUDE HEALTH®

Participant Demographics

How many pediatric patients (age >1 month to 18 years) with localized, nonmetastatic solid tumors have you treated with cisplatin in the past 12 months? (n = 26*)

How many adolescent and/or young adult (AYA) patients (age 15–39) with localized, nonmetastatic solid tumors have you treated with cisplatin in the past 12 months? (n = 24†)

How many adult patients (age >39 years) with localized, nonmetastatic solid tumors have you treated with cisplatin in the past 12 months? (n = 27‡)

*Four advisors did not respond; †Six advisors did not respond; ‡Three advisors did not respond.

Report Snapshot: Agenda

Time	Topic
10 min	**Introduction** • Program overview and objectives • ARS questions
20 min	**Management of Cisplatin-Induced Ototoxicity in Localized, Nonmetastatic Solid Tumors**
25 min	**Moderated Discussion**
5 min	**Key Takeaways and Adjourn**

APTITUDE HEALTH®

CASES

Discussion Summary

Insights From Discussion (1/5)

Perceptions of Cisplatin-Induced Ototoxicity

Insights From Discussion (2/5)

Experience Monitoring for Cisplatin-Induced Ototoxicity Symptoms

Insights From Discussion (3/5)

Experience Managing Cisplatin-Induced Ototoxicity Symptoms

Insights From Discussion (4/5)

Perceptions of Sodium Thiosulfate (STS) Clinical Data

Insights From Discussion (5/5)

Clinical Considerations for STS Use in Ototoxicity Prevention

APTITUDE HEALTH®

CASES

Advisor Key Takeaways

Advisor Key Takeaways (Cancer Center of Kansas*)

ADVISOR	ADVISOR
> I'd never heard of this drug so that's my big key	> I really didn't know about this drug

Advisor Key Takeaways (Northeast Region)

ADVISOR	ADVISOR
> In the realm for ototoxicity, I think [STS] is a great option	> I think it's definitely promising; 45% [reduction in
1	5
2	6
3	7
4	8

Advisor Key Takeaways (Southeast Region)

ADVISOR	ADVISOR
> This is a protective agent, reduce auditory toxicity,	
1	6
2	6
3	7
4	8

Advisor Key Takeaways (Chicago/Ohio Valley Region*)

ADVISOR	ADVISOR
> Reduction in the patients that were treated [was] about	> The data is very convincing
1	5
2	6
3	7
4	8

Advisor Key Takeaways (Pacific Region)

ADVISOR		ADVISOR	
1	> I'm glad we have an agent available for ototoxicity > I have a better understanding of sequencing therapies > I really wasn't that familiar with polatuzumab and tafasitamab but now I have a better understanding of these drugs and have a better idea of when to use them in my practice	5	> I'd like to see it in the NCCN Guidelines so that I can > For relapsed/refractory patients it's nice to have different options besides R-ICE and auto or going to CAR-T
2	> I have a better understanding of some of my relapse options > I'm particularly interested in the tafasitamab and hope that tafa and Rev would be tolerated for a second-line option for my very elderly patients > There's a lot more enthusiasm for targeted therapy and for things like polatuzumab that may offer lesser side effects	6	> I'm hoping that some of these second-line agents will get added onto frontline and hopefully improve the cure rate
3	> It was great to hear about innovations and what's coming down the pipeline for relapsed/refractory	7	> Very interesting to learn about all these relapsed/refractory treatments, specifically the bispecific antibodies > A lot of options coming up in the future. The only issue will be to learn how to sequence these drugs
4	> There's a lot of good options for second line than just CAR-T and transplant with decent side effect profile and good response rates > Sequencing is an issue	8	> Still R-CHOP is the standard

APTITUDE HEALTH®

CASES

ARS Data

Most Advisors Are at Least Moderately Concerned Regarding Cisplatin-Induced Ototoxicity

*Two advisors did not respond.

93% of Advisors Estimated That Up to 50% of Patients With Localized Disease Experience Hearing Loss and/or Tinnitus After Cisplatin Treatment

*Three advisors did not respond.

Nearly Half of Advisors Reported That Approximately 1%–10% of Patients With Localized Disease Experience Hearing Loss and/or Tinnitus After Carboplatin Treatment

CASES

*One advisor did not respond.

66% of Oncologists Indicated That Up to 25% of Cisplatin-Treated Patients With Hearing Loss and/or Tinnitus Experience Long-Term Effects of Ototoxicity

CASES

*One advisor did not respond.

41% of Advisors Do Not Currently Monitor for Symptoms of Ototoxicity in Cisplatin-Treated Patients

Do you currently perform audiologic monitoring for ototoxicity in cisplatin-treated patients

*One advisor did not respond.

The Majority of Oncologists Who Monitor for Cisplatin-Induced Ototoxicity Do So Before, During, and After Treatment

*Two advisors did not respond.

Most Advisors Manage Symptoms of Ototoxicity by Stopping or Reducing Cisplatin and/or Referring Patients to Audiology

*One advisor did not respond.

None of the Advisors Had Experience With Sodium Thiosulfate Injection to Reduce the Risk of Cisplatin-Induced Ototoxicity

CASES

*Two advisors did not respond.

Most Advisors (76%) Value Inclusion in NCCN Guidelines as a Top Factor for Treatment Options in the Management of Cisplatin-Induced Toxicities

*One advisor did not respond.

APTITUDE HEALTH®

CASES

ARS Data by Region/Practice

Participant Demographics

Participant Demographics by Region/Practice (1/3)

How many pediatric patients (age >1 month to 18 years) with localized, nonmetastatic solid tumors have you treated with cisplatin in the past 12 months?



Participant Demographics by Region/Practice (2/3)

How many adolescent and/or young adult (AYA) patients (age 15–39) with localized, nonmetastatic solid tumors have you treated with cisplatin in the past 12 months?



Participant Demographics by Region/Practice (3/3)

How many adult patients (age >39 years) with localized, nonmetastatic solid tumors have you treated with cisplatin in the past 12 months?



APTITUDE HEALTH®

CASES

ARS Data by Practice

CASES in Ototoxicity: Cancer Center of Kansas (Region 1)

July 25, 2024

Insights From ARS Data: Cancer Center of Kansas (Region 1)

CASES

	Topics	Data and Insights
Cisplatin-Induced Ototoxicity	Concerns With Ototoxicity	▶
	Experience With Cisplatin-Induced Ototoxicity	▶
	Experience With Carboplatin-Induced Ototoxicity	▶
	Long-Term Effects of Ototoxicity	▶
	Audiologic Monitoring Experience (1/2)	▶
	Audiologic Monitoring Experience (2/2)	▶
	Ototoxicity Symptom Management	▶
	STS Injection Experience	▶
	Clinical Decision Factors for Toxicity Management	▶

Concerns With Ototoxicity

Experience With Cisplatin-Induced Ototoxicity

Experience With Carboplatin-Induced Ototoxicity

Long-Term Effects of Ototoxicity

Audiologic Monitoring Experience (1/2)

Audiologic Monitoring Experience (2/2)

Ototoxicity Symptom Management

STS Injection Experience

FOR EXAMPLE PURPOSES ONLY

*One advisor did not respond.

Clinical Decision Factors for Toxicity Management

APTITUDE HEALTH®

CASES

ARS Data by Region

CASES in Ototoxicity: Northeast Region

September 12, 2024

Insights From ARS Data: Northeast Region

CASES

	Topics	Data and Insights
Cisplatin-Induced Ototoxicity	Concerns With Ototoxicity	
	Experience With Cisplatin-Induced Ototoxicity	
	Experience With Carboplatin-Induced Ototoxicity	
	Long-Term Effects of Ototoxicity	
	Audiologic Monitoring Experience (1/2)	
	Audiologic Monitoring Experience (2/2)	
	Ototoxicity Symptom Management	
	STS Injection Experience	
	Clinical Decision Factors for Toxicity Management	

Concerns With Ototoxicity

Experience With Cisplatin-Induced Ototoxicity

Experience With Carboplatin-Induced Ototoxicity

Long-Term Effects of Ototoxicity

Audiologic Monitoring Experience (1/2)

Audiologic Monitoring Experience (2/2)



Ototoxicity Symptom Management

STS Injection Experience

Clinical Decision Factors for Toxicity Management

APTITUDE HEALTH®

CASES

ARS Data by Region

CASES in Ototoxicity: Southeast Region

September 24, 2024

Insights From ARS Data: Southeast Region

CASES

	Topics	Data and Insights
Cisplatin-Induced Ototoxicity	Concerns With Ototoxicity	
	Experience With Cisplatin-Induced Ototoxicity	
	Experience With Carboplatin-Induced Ototoxicity	
	Long-Term Effects of Ototoxicity	
	Audiologic Monitoring Experience (1/2)	
	Audiologic Monitoring Experience (2/2)	
	Ototoxicity Symptom Management	
	STS Injection Experience	
	Clinical Decision Factors for Toxicity Management	

Concerns With Ototoxicity

*One advisor did not respond.

Experience With Cisplatin-Induced Ototoxicity

*One advisor did not respond.

Experience With Carboplatin-Induced Ototoxicity

Long-Term Effects of Ototoxicity

Audiologic Monitoring Experience (1/2)

Audiologic Monitoring Experience (2/2)

Ototoxicity Symptom Management

STS Injection Experience

Clinical Decision Factors for Toxicity Management

APTITUDE HEALTH®

CASES

ARS Data by Region

CASES in Ototoxicity: Chicago/Ohio Valley Region

September 23, 2024

Insights From ARS Data: Chicago/Ohio Valley Region

CASES

	Topics	Data and Insights
Cisplatin-Induced Ototoxicity	Concerns With Ototoxicity	
	Experience With Cisplatin-Induced Ototoxicity	
	Experience With Carboplatin-Induced Ototoxicity	
	Long-Term Effects of Ototoxicity	
	Audiologic Monitoring Experience (1/2)	
	Audiologic Monitoring Experience (2/2)	
	Ototoxicity Symptom Management	
	STS Injection Experience	
	Clinical Decision Factors for Toxicity Management	

Concerns With Ototoxicity

*One advisor did not respond.

Experience With Cisplatin-Induced Ototoxicity

*Two advisors did not respond.

Experience With Carboplatin-Induced Ototoxicity

*One advisor did not respond.

Long-Term Effects of Ototoxicity



*One advisor did not respond.

Audiologic Monitoring Experience (1/2)

*One advisor did not respond.

Audiologic Monitoring Experience (2/2)



*Two advisors did not respond.

Ototoxicity Symptom Management

*One advisor did not respond.

STS Injection Experience

*One advisor did not respond.

Clinical Decision Factors for Toxicity Management

*One advisor did not respond.

APTITUDE HEALTH®

CASES

ARS Data by Region

CASES in Ototoxicity: Pacific Region

September 24, 2024

Insights From ARS Data: Pacific Region

CASES

	Topics	Data and Insights
Cisplatin-Induced Ototoxicity	Concerns With Ototoxicity	▶
	Experience With Cisplatin-Induced Ototoxicity	▶
	Experience With Carboplatin-Induced Ototoxicity	▶
	Long-Term Effects of Ototoxicity	▶
	Audiologic Monitoring Experience (1/2)	▶
	Audiologic Monitoring Experience (2/2)	▶
	Ototoxicity Symptom Management	▶
	STS Injection Experience	▶
	Clinical Decision Factors for Toxicity Management	▶

Concerns With Ototoxicity

Experience With Cisplatin-Induced Ototoxicity



Experience With Carboplatin-Induced Ototoxicity

Long-Term Effects of Ototoxicity

Audiologic Monitoring Experience (1/2)

Audiologic Monitoring Experience (2/2)



Ototoxicity Symptom Management



STS Injection Experience

Clinical Decision Factors for Toxicity Management

APTITUDE HEALTH®

US 5901-B Peachtree Dunwoody Road
Suite 415, Atlanta, GA 30328, US

EU Laan van Nieuw Oost-Indië 133 F
2593 BM The Hague, the Netherlands

UK 6th Floor, 2 Kingdom Street
London, W2 6BD, United Kingdom

aptitudehealth.com